CONTENTS

	Page
Contents	(viii)
List of Tables	(xii)
List of Figures	(xiii)
List of Abbreviations and symbols	(xv)
Chapter	
1 Introduction	1
2 Literature review	4
2.1 Characteristics of breast cancer	4
2.1.1 Breast anatomy and physiology	4
2.1.2 Breast cancer	4
2.1.3 Classification of the breast cancer	6
2.1.3.1 Invasive carcinoma	6
2.1.3.2 Carcinoma *in situ*	7
2.1.3.3 Cancer of the male breast	8
2.2 Risk factors	9
2.2.1 Age	9
2.2.2 Family history	10
2.2.3 Hormonal and reproductive factors	10
2.2.4 Race / Ethnicity	12
2.2.5 Smoking	13
2.2.6 Breastfeeding	14
2.2.7 Food	14
2.2.8 Benign breast disease	15
2.2.9 Environmental factor	15
2.2.10 Genetic factor	15
2.3 Breast cancer susceptibility gene 1 or *BRCA1*	17
2.4 Structure and function of the BRCA1 protein	18
2.5 Pathobiology of hereditary breast cancer	20

CONTENTS (Continued)

	Page
2.6 Mutation spectrum of *BRCA1*	20
2.7 Genetic testing for the *BRCA1* gene	24
2.8 The screening techniques	26
2.8.1 Single-stranded conformation polymorphism (SSCP)	28
2.8.2 Heteroduplex analysis (HA)	28
2.8.3 Protein truncation test (PTT)	29
2.8.4 Direct sequencing (DS)	30
2.9 Recommendations of high risk women	30
2.9.1 Breast self-examination (BSE)	31
2.9.2 Clinical breast examination (CBE)	31
- Mammography	31
- Ultrasound	32
- Magnetic resonance imaging (MRI)	32
2.9.3 Prevention surgery	32
2.9.4 Chemoprevention	33
3 Materials and Methods	34
3.1 Materials	34
3.1.1 Clinical specimens	34
3.1.2 Materials for genomic DNA	34
3.1.3 Materials for polymerase chain reaction (PCR)	35
3.1.4 Materials for agarose gel electrophoresis	35
3.1.5 Materials for single-stranded conformation polymorphism	35
3.1.6 Materials for DNA sequencing	36
3.1.7 PCR primers specific for *BRCA1* gene	36
3.2 Instruments	38
3.3 Methods	38
3.3.1 Genomic DNA extraction	38
3.3.1.1 Collection of blood samples	38
3.3.1.2 Separation of white blood cells	39

CONTENTS (Continued)

	Page
3.3.1.3 DNA extraction from white blood cells	39
3.3.2 The purity and concentration of DNA	39
3.3.3 Screening for *BRCA1* mutations	40
3.3.3.1 DNA amplification	40
3.3.3.2 Analysis of the exon-intron 7 boundary sequence of Patient ID 17 and the patient's daughter	40
3.3.3.3 Agarose gel electrophoresis	42
3.3.3.4 Single-Stranded Conformation Polymorphism	43
3.4 Data analysis	44
4 Results	45
4.1 Clinical / pathological characteristics of the patients	45
4.2 Purity and concentrations of the genomic DNA	48
4.3 PCR optimization for the amplification of *BRCA1* exons	49
4.3.1 Magnesium concentration	51
4.3.2 Primer concentration	51
4.3.3 Template concentration	52
4.3.4 PCR programs	52
4.3.5 Annealing temperature	52
4.4 Single-Stranded Conformation Polymorphism analysis of *BRCA1* exons	55
4.5 Direct sequencing of *BRCA1* exons	73
4.6 Single-Stranded Conformation Polymorphism (SSCP) analysis of patient's healthy daughter (ID18)	75
4.7 Sequence analysis of the exon-intron 7 boundary of patient ID 17 and the patient's daughter (ID 18)	78
4.8 *Pfu* DNA polymerase on patients whose exons exhibiting changes in SSCP analysis	78
5 Discussion	82

CONTENTS (Continued)

	Page
5.1 Pathological background of the patients	82
5.2 PCR-SSCP analysis	83
5.3 *BRCA1* mutations in Thai breast cancer patients	86
6 Conclusion	102
Bibliography	103
Appendix	127
Vitae	135

LIST OF TABLES

Table		Page
2.1	Percentage of breast tumors classified by locations	6
2.2	Cumulative risks (standard error) of breast cancer among relatives with *BRCA1* mutation	16
2.3	Estimated cancer risks in *BRCA1* mutation carriers	16
2.4	Total number of mutation, polymorphism and variants of *BRCA1* from Breast Cancer Information Core (BIC) database	21
2.5	Frequencies of *BRCA1* mutation types	22
2.6	The advantages and disadvantages of each method used in routine diagnosis	27
3.1	Oligodeoxyribonucleotide primers used for PCR amplification and nucleotide sequences	36
3.2	The conditions of thermal cycle	40
3.3	Oligodeoxyribonucleotide primers used for PCR amplification of exon-intron 7 boundary and nucleotide sequences	42
3.4	Preparation of 10% non-denaturing polyacrylamide gel	43
4.1	Percentage of the patients classified by clinical/pathological characteristics	45
4.2	Summary of purity and concentrations of the genomic DNA	48
4.3	Summary of optimal conditions for PCR amplification of *BRCA1* exons	49
4.4	Summary of selected patients whose exons exhibiting changes in electrophoretic mobility on 10% non-denaturing polyacrylamide gel	55
5.1	Examples of disorders of trinucleotide repeat expansions and deletion	95
5.2	DNA repeats, symmetry elements and alternative DNA structures	99
7	The family history information and clinical/pathological characteristics of 17 patients	128

LIST OF FIGURES

Figure		Page
2.1	Schematic illustration of breast anatomy, lymphatic drainage of the breast and breast position	5
2.2	Normal breast tissue	8
2.3	Cancerous breast tissue (ductal carcinoma)	8
2.4	Cancerous breast tissue (lobular carcinoma)	9
2.5	Age-standardized incidence and mortality rates for breast cancer	13
2.6	Two-hit hypothesis of tumor suppressor gene	17
2.7	Schematic diagram of the BRCA1 protein and sites of its interaction with other proteins	19
2.8	Suggested algorithm for genetic screening in women with family history of breast cancer	25
3.1	The exon-intron 7 boundary sequences in the *BRCA1* gene	41
4.1	The pedigrees of 5 patients with a family history of cancer	46
4.2	The effect of primer concentration on PCR amplification of *BRCA1* gene using BRCF3 and BRCR3 primers	51
4.3A-E	The pattern of PCR products amplified with each pair of primer at designated annealing temperature of *BRCA1* exons	52
4.4-4.19	The typical SSCP results for each exon of *BRCA1* of 31 Thai patients	56
4.20	SSCP analysis of the PCR fragment of *BRCA1* exons of patient ID 17	72
4.21	Genomic sequences of the *BRCA1* IVS7+34_47 del TTCTTTTCTTTTTT deletion	73
4.22	Pedigree of patient ID 17	74
4.23	SSCP analysis of the PCR fragment of *BRCA1* exons of ID 18	76
4.24	Genomic sequences of the *BRCA1* exon 7 - intron 7 boundary in the sense and antisense strands of the patient ID 17's healthy daughter	77
4.25	Single-stranded conformation polymorphism of PCR products with silver staining	78

LIST OF FIGURES (Continued)

Figure		Page
4.26	Genomic sequence of the *BRCA1* IVS7+50_63del TTCTTTTTTTTTTT deletion using *Pfu* DNA polymerase in the sense And antisense strand sequences of the patient ID 17	80
4.27	Genomic sequence of the *BRCA1* exon-intron 7 boundary using *Pfu* DNA polymerase in the sense and antisense strand sequences of the healthy patient's daughter	81
5.1	Deduced normal nucleotide sequence containing the $(TTC)_7.(GAA)_7$ repeat tract in intron	91
5.2	Proposed looped structure involved in IVS7+34_47delTTCTTTTCTTTTTT	92
5.3	Location of repeat tract in triplex repeat disease genes	93
5.4	Location of repeat tract in triplex repeat of *BRCA1* gene	94
5.5	Non-B DNA conformations involved in genomic rearrangements	96
5.6	Proposed intramolecular triplex DNA structures and looped structure For IVS7+34_47delTTCTTTTCTTTTTT of the patient ID 17	97
5.7	Proposed looped structure involved in IVS7+50_63 delTTCTTTTTTTTTTT in the sense strand and in IVS7+34_47 delAAGAAAAG AAAAA in the antisense strand of the proband's daughter	98
5.7A-C	Proposed intramolecular triplex DNA structures and looped structure formed for the IVS7+50_63delTTCTTTTTTTTTTT and IVS7+34_47 delAAGAAAAG AAAAA of the proband's daughter	100

LIST OF ABBREVIATIONS AND SYMBOLS

$AgNO_3$	=	silver nitrate
ASO	=	allele-specific oligonucleotide hybridization
ASR	=	age-standardized incidence rates
BAP1	=	BRCA1-associated proteins
BARD	=	BRCA1-associated RING-domain protein
BIC	=	breast information core
bp	=	base pair
BRCA1	=	breast cancer susceptibility gene 1 / breast cancer suppressor gene 1
BRCT	=	BRCA1 *C*-terminal domain
BSE	=	breast self-examination
CBE	=	clinical breast examination
CCM	=	chemical cleavage mismatch
°C	=	degrees celsius
dATP	=	deoxyadenosine triphosphate
DCIS	=	ductal carcinoma *in situ*
dCTP	=	deoxycytidine triphosphate
DDF	=	dideoxy fingerprinting assay
DDT	=	dichlorodiphenyl trichloroethane
DGGE	=	denaturing gradient gel electrophoresis
dGTP	=	deoxyguanosine triphosphate
dHPLC	=	denaturing high performance liquid chromatography
DNA	=	deoxyribonucleic acid
dNTP	=	deoxynucleotide triphosphate
DS	=	direct sequencing
dTTP	=	deoxythymidine triphosphate
EDTA	=	ethylenediaminetetraacetate
ERE	=	estrogen responsive element
ER-α	=	estrogen receptor alpha

LIST OF ABBREVIATIONS AND SYMBOLS (Continued)

Fig	=	figure
HA	=	heteroduplex analysis
hr	=	hour
HRT	=	hormone replacement therapy
ID	=	identity
IDC	=	invasive ductal carcinoma
ILC	=	invasive lobular carcinoma
IVS	=	noncoding intervening sequence
KCl	=	potassium chloride
LCIS	=	lobular carcinoma *in situ*
LIQ	=	lower inner quadrant
LOH	=	loss of heterozygosity
LOQ	=	lower outer quadrant
mg	=	milligram
$MgCl_2$	=	magnesium chloride
ml	=	millilitre
mM	=	millimolar
MRI	=	magnetic resonance imaging
mRNA	=	messenger ribonucleic acid
ng	=	nanogram
NLS	=	nuclear localization signal domain
OCP	=	oral contraceptive
OD_{260}	=	optical density at 260 nm
OD_{280}	=	optical density at 280 nm
PCBs	=	polychlorinated biphenyls
PCR	=	polymerase chain reaction
PTT	=	protein truncation test
Rb	=	retinoblastoma gene
rpm	=	revolutions per minute

LIST OF ABBREVIATIONS AND SYMBOLS (Continued)

SDS	=	sodium dodecyl sulphate
SSCP	=	single-stranded conformation polymorphism
TAE	=	tris-acetate- ethylenediaminetetraacetate buffer
TE	=	tris-ethylenediaminetetraacetate buffer
TEMED	=	*N, N, N′, N′* -tetramethylethylenediamine
Tris	=	tris (hydroxymethyl) aminomethane
T_m	=	melting temperature
UIQ	=	upper inner quadrant
UOQ	=	upper outer quadrant
UV	=	ultraviolet
WBC	=	white blood cell
μM	=	micromolar
μg	=	microgram